Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy MediWound stock

Own MediWound stock in just a few minutes.

MediWound Ltd is a biotechnology business based in the US. MediWound shares (MDWD) are listed on the NASDAQ and all prices are listed in US Dollars. MediWound employs 75 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in MediWound

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MDWD – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

MediWound share price

Use our graph to track the performance of MDWD stocks over time.

MediWound shares at a glance

Information last updated 2021-03-10.
52-week range$1.44 - $6.07
50-day moving average $5.35
200-day moving average $4.15
Wall St. target price$7.67
PE ratio 27.0714
Dividend yield N/A (0%)
Earnings per share (TTM) $0.24

Buy MediWound shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MediWound stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is MediWound under- or over-valued?

Valuing MediWound stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MediWound's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MediWound's P/E ratio

MediWound's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 27x. In other words, MediWound shares trade at around 27x recent earnings.

That's comparable to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29).

MediWound's EBITDA

MediWound's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.2 million.

The EBITDA is a measure of a MediWound's overall financial performance and is widely used to measure a its profitability.

MediWound financials

Revenue TTM $21.8 million
Gross profit TTM $7.5 million
Return on assets TTM -15%
Return on equity TTM -82.67%
Profit margin -42.26%
Book value $0.27
Market capitalisation $150.9 million

TTM: trailing 12 months

Shorting MediWound shares

There are currently 33,009 MediWound shares held short by investors – that's known as MediWound's "short interest". This figure is 53.1% up from 21,560 last month.

There are a few different ways that this level of interest in shorting MediWound shares can be evaluated.

MediWound's "short interest ratio" (SIR)

MediWound's "short interest ratio" (SIR) is the quantity of MediWound shares currently shorted divided by the average quantity of MediWound shares traded daily (recently around 366766.66666667). MediWound's SIR currently stands at 0.09. In other words for every 100,000 MediWound shares traded daily on the market, roughly 90 shares are currently held short.

However MediWound's short interest can also be evaluated against the total number of MediWound shares, or, against the total number of tradable MediWound shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MediWound's short interest could be expressed as 0% of the outstanding shares (for every 100,000 MediWound shares in existence, roughly 0 shares are currently held short) or 0.0016% of the tradable shares (for every 100,000 tradable MediWound shares, roughly 2 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against MediWound.

Find out more about how you can short MediWound stock.

MediWound share dividends

We're not expecting MediWound to pay a dividend over the next 12 months.

MediWound share price volatility

Over the last 12 months, MediWound's shares have ranged in value from as little as $1.4427 up to $6.07. A popular way to gauge a stock's volatility is its "beta".

MDWD.US volatility(beta: 1.54)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MediWound's is 1.5363. This would suggest that MediWound's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

MediWound overview

MediWound Ltd. , a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel. .

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site